Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI.

NCT04710628 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT04710628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04710628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI.
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
September 21, 2021
Completion date
February 16, 2026
Enrollment
43 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic thymic carcinoma, thymoma type b3